Human C1-Esterase Inhibitor
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
- Human C1-Esterase Inhibitor
- Human C1-Esterase Inhibitor: From Hereditary Angioedema to Severe Nonproliferative Diabetic Retinopathy
Human C1-Esterase Inhibitor: From Hereditary Angioedema to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Human C1-esterase inhibitor (C1-INH, DrugBank DB06404) is a plasma-derived serine protease inhibitor clinically known for treating hereditary angioedema (HAE) by regulating the complement, contact-activation, and coagulation cascades — though this original-indication detail is not captured in the current evidence pack. The TxGNN model predicts it may be effective for Severe Nonproliferative Diabetic Retinopathy, but this specific prediction currently has 0 clinical trials and 0 publications supporting it — it is a pure knowledge-graph-embedding signal with no direct or indirect literature backing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not captured in evidence pack (no Taiwan license/MOA data returned; C1-INH is clinically established for hereditary angioedema, per general pharmacological knowledge — not verified against this evidence pack) |
| Predicted New Indication | Severe Nonproliferative Diabetic Retinopathy |
| TxGNN Prediction Score | 99.61% |
| Evidence Level | L5 |
| Market Status (Taiwan) | 未上市 (Not marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this drug in the evidence pack (Data Gap DG002, severity High). Based on what evidence is present in the accompanying repurposing rationale, human C1-esterase inhibitor (C1-INH/SERPING1) is a serine protease inhibitor that primarily suppresses the classical complement pathway (C1r, C1s) and the lectin pathway (MASP1/2), and also acts on the contact-activation system (kallikrein, activated Factor XII).
Severe nonproliferative diabetic retinopathy is a late-stage subtype of diabetic retinopathy (DR), a disease with documented complement-pathway involvement — C1q deposition, local inflammation, and microvascular thrombosis. Theoretically, C1-INH’s inhibition of complement activation could plausibly attenuate this inflammatory and microvascular injury process. Notably, a related TxGNN prediction in the same evidence pack (rank 3, plain “diabetic retinopathy,” score 99.25%) is supported by one genetic-association study linking complement pathway genes (SERPING1, C5) to DR susceptibility — this offers indirect mechanistic plausibility for the complement–DR link in general.
However, for the specific candidate evaluated here (severe nonproliferative DR), no clinical trial or literature evidence exists at all. The mechanistic link is explicitly flagged in the source data as theoretical only, and the high TxGNN score may reflect shared complement-related graph nodes rather than a validated pharmacological relationship. This prediction should be read as hypothesis-generating, not evidence-supported.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA warnings/contraindications are a Blocking data gap (DG001) — this must be resolved before any S1 safety review can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate sits at evidence level L5 (model prediction only) — there are zero clinical trials and zero publications directly supporting C1-INH use in severe nonproliferative diabetic retinopathy. The mechanistic rationale is inferred by analogy to a related, still weakly-supported prediction (plain diabetic retinopathy, backed only by a Tier 3 genetic-association study, not an interventional study of C1-INH itself). The drug is also not currently marketed in Taiwan (0 NDAs).
To proceed, the following is needed:
- Resolve Blocking data gap DG001: TFDA label warnings/contraindications (required before any safety review)
- Resolve High-priority data gap DG002: confirmed mechanism of action from DrugBank
- Original approved indication(s) for this drug, to properly assess similarity to the new indication
- At minimum, preclinical or mechanistic studies directly testing C1-INH in a diabetic retinopathy model, before this moves beyond a research question
- Continued monitoring of the related “diabetic retinopathy” (non-severe-specific) prediction, which has marginally stronger — though still indirect — literature support
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.